Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression.
Guy M GoodwinScott T AaronsonOscar AlvarezPeter C ArdenAnnie BakerJames C BennettCatherine BirdRenske E BlomChristine BrennanDonna BruschLisa BurkeKete Campbell-CokerRobin Carhart-HarrisJoseph CattellAster DanielCharles DeBattistaBoadie W DunlopKatherine EisenDavid FeifelMacKenzie ForbesHannah M HaumannDavid J HellersteinAstrid I HoppeMuhammad I HusainLuke A JelenJeanine KamphuisJulie KawasakiJohn R KellyRichard E KeyRonit KishonStephanie Knatz PeckGemma KnightMartijn H B KoolenMelanie LeanRasmus W LichtJessica L Maples-KellerJan MarsLindsey MarwoodMartin C McElhineyTammy L MillerArvin MirowSunil MistryTanja Mletzko-CroweLiam N ModlinRené E NielsenElizabeth M NielsonSjoerd R OfferhausVeronica O'KeaneTomáš PáleníčekDavid PrintzMarleen C RademakerAumer van ReemstFrederick ReinholdtDimitris RepantisJames RuckerSamuel RudowSimon RuffellA John RushRobert A SchoeversMathieu SeynaeveSamantha ShaoJair C SoaresMetten SomersSusan C StansfieldDiane SterlingAaron StrockisJoyce TsaiLucy VisserMourad WahbaSamuel WilliamsAllan H YoungPaula YwemaSidney ZisookEkaterina MalievskaiaPublished in: The New England journal of medicine (2022)
In this phase 2 trial involving participants with treatment-resistant depression, psilocybin at a single dose of 25 mg, but not 10 mg, reduced depression scores significantly more than a 1-mg dose over a period of 3 weeks but was associated with adverse effects. Larger and longer trials, including comparison with existing treatments, are required to determine the efficacy and safety of psilocybin for this disorder. (Funded by COMPASS Pathfinder; EudraCT number, 2017-003288-36; ClinicalTrials.gov number, NCT03775200.).